Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100 nm is attracting attention as a means to improve nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand, or electric charge or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs, and EVs and their applications for DDSs.
including their use as artificial cell membranes, carriers for drug delivery systems (DDSs), encapsulating agents for food ingredients, and analytical tools [2] [3] [4] [5] [6] [7] . It is possible to encapsulate a variety of drugs in the lipid bilayer membrane or to encapsulate them into the hollow structure itself [8] [9] [10] [11] [12] . Although the LNPs, including liposomes, showed good biological compatibility, additional improvements were required for practical applications such as increasing their stability, retention time in blood, and delivery efficiency of drugs or nucleic acid molecules to the targeting cells. To overcome these drawbacks, several strategies have been proposed [13] [14] [15] [16] [17] [18] [19] [20] [21] , such as surface modification with PEGylated lipids, development of pH-sensitive cationic lipids, and design of multi-functionalized LNPs, as shown in Fig. 1(a) . The performance of LNPs has dramatically improved by applying these strategies. The PEGylated LNP called Doxil® was approved as an anticancer drug, and pH-sensitive cationic LNPs are being evaluated in a clinical trial.
Extracellular vesicles (EVs) are also significant lipid-based vesicles for DDS applications, diagnostics, and lipid science [22] [23] [24] [25] . In the last decade, EVs, especially exosomes, have attracted the attention of many researchers who want to understand intercellular communications and relationships with diseases [26] [27] [28] [29] . Exosomes have a unilamellar lipid bilayer, and their sizes range from 30 to 100 nm. In addition, exosomes are composed of proteins, mRNA, miRNA, and DNA in an aqueous core, and membrane proteins, MHC (major histocompatibility complex) molecules, and integrins are embedded in the phospholipid membrane, as shown in Fig. 1(b) . From the viewpoint of DDS applications, exosomes offer desirable features as carriers for nucleic acid medicines. In other words, exosomes may be regarded as DDS carriers produced in the human body. First, exosomes can stably deliver proteins and nucleic acids to targeted cells. Second, their sizes can avoid exclusion by glomeruli, and it may be possible for the exosomes to accumulate in tumor tissues by the enhancement permeability and retention (EPR) effect [30, 31] , which is the same as that for LNPs. Third, DNA, RNA, and other compounds can be encapsulated into exosomes after collecting them from a cell culture supernatant or serum. For these reasons, exosomes are expected to be powerful carriers for DDSs [32] [33] [34] [35] .
The LNPs and EVs allow two targeting modes, namely, active targeting and passive targeting (Fig. 2) [36] [37] [38] [39] . Active targeting is achieved by conjugating ligands to the LNPs or EVs that bind to a specific target cell receptor. By contrast, passive targeting is achieved by the EPR effect, which is an accumulation of LNPs in tumor tissues due to the presence of leaky blood vessels and dysfunctional lymphatic drainage in tumor tissues. The molecular ratio of lipids must be adjusted to obtain the best therapeutic performance. To produce suitable LNP vesicles for DDS applications, a variety of production techniques have been developed such as the hydration method, freeze-thawing method, extrusion method, sonication method, and organic solvent injection method [40] [41] [42] . For EVs, an ultracentrifuge or a specific isolation kit was employed for the separation of exosomes from cell culture supernatant and body fluid [43] [44] [45] [46] . These techniques have been established as the gold standard methods for the applications using lipid-based vesicles. However, these conventional tools still need to be further improved to develop high-performance DDS carriers and to separate exosomes from biofluids under less-invasive conditions.
Recently, the effect of nanocarrier size on the drug (or siRNA) delivery efficiency was reported to increase understanding of the in vivo kinetics of nanomedicines [47] [48] [49] [50] . For polymeric micelles, more 30-nm-sized micelles accumulated in stromal-rich tumor tissues than 70-nm-sized micelles did [47] . In addition, LNPs were also shown to have similar in vivo kinetics as that of the polymeric micelles [48] . Therefore, the production of precisely size-controlled nanocarriers is one of the essential topics for the next-generation DDS carriers and nanomedicine. It has been suggested that the precise size separation and less-invasive collection technique of exosomes would also be a novel gold standard for considering the application of exosomes in DDSs. However, the preparation of precisely size-controlled LNPs and exosomes is difficult by the conventional methods.
Over the last few decades, a number of microfluidic devices and techniques have been developed, and their applications have led to a revolution in the life science field [51] [52] [53] [54] . Notably, the application of microfluidic devices in organ-on-a-chip [55, 56] , drug discovery and drug delivery [57] [58] [59] , protein and DNA analyses [60] [61] [62] , cell separation and analysis [63] [64] [65] , and diagnostics [66] [67] [68] has attracted the attention of researchers worldwide. In general, microfluidic devices offer a reduced consumption of valuable samples, a rapid molecular diffusion due to the short microchannel length, a good reaction time controllability, a large surface-to-volume ratio, and a high separation efficiency based on the variety of available mechanisms (hydrodynamics, centrifugal force, ultrasonic sound wave, and electric field). Because of the excellent characteristics, the applications of microfluidic devices have been expanded to diagnostics, biomolecular analysis, cell analysis, organ on a chip, and nanomaterial synthesis. Microfluidic-based platforms have also allowed researchers to overcome the problems in the preparation of size-controlled LNPs and less-invasive separation of EVs including exosomes for DDS applications. In this paper, we mainly overview the production methods of the LNPs using microfluidic devices for DDS applications. In particular, we focus on the production strategies and methods for size-controlled LNPs in the range 20-200 nm. We also introduce the separation techniques of EVs using microfluidic devices and present some applications of size-controlled LNPs for DDSs.
Production of LNPs using microfluidic devices
In fact, the principles of the LNP formation mechanism using microfluidic devices are the same as those for conventional methods. The LNP production methods can be classified into hydration, organic solvent injection, detergent removal, and reverse-phase evaporation vesicle methods [69] [70] [71] [72] . The hydration method is the most common method for producing multilamellar large vesicles (MLVs; 100-1000 nm). First, a lipid film is obtained by evaporating an organic solution of lipid in a tube or flask, and then, an aqueous solution (for example, PBS) is introduced to produce MLVs. The MLVs undergo size tuning to produce small unilamellar vesicles (SUVs; b100 nm) by sonication and extrusion [73, 74] . The vesicle sizes are controlled by irradiation time and power (sonication) and by membrane pore size (extrusion). After producing the SUVs, a freeze-thawing process is used for loading drugs into the LNPs [75] . The organic solvent injection method can produce the LNPs in a single step. The concentration of lipid, injected volume and rate of lipid solution into the aqueous solution, and mixing rate are important parameters for controlling the LNP size. The detergent removal method is based on the formation of micelles, which are composed of detergent and lipid molecules, and the removal of detergents by dialysis. The detergent removal method is suitable for the solubilization and reconstitution of membrane proteins, because it does not require the use of any organic solvents and freeze-thawing cycles.
Microfluidic-based LNP and liposome production effectively utilizes fluid dynamics, the surface or interface of the microfluidic devices, and the structure of the devices. Microfluidic devices can produce LNPs of a wider size range including liposomes and of better particle size distribution than conventional methods [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] . Hydrodynamics is an indispensable mechanism for producing LNPs using microfluidic devices, and it provides wide size range. We have reported a unique hydration-based LNP production method called the touch-and-go method, as shown in Fig. 3 [82] . Lipid bilayer films are formed on the glass surface, and then, the condensed DNA cores are introduced into the microfluidic device. The core particles touch the surfaces of lipid films and are wrapped in the lipid bilayer. Finally, they are released from the glass surface as LNPs. Several types of other unique liposome production methods have also been developed including pulsed jetting [87, 88] , microdroplet or emulsion-based [89] [90] [91] , electroformation [92] , extrusion [93] , and jet-freezing [94] methods.
3. Strategies for the formation of size-controlled LNPs for DDSs by using microfluidic devices
Microfluidic-based LNP production
In this section, we particularly focus on the preparation of 20-to 100-nm size-controlled LNPs and review the strategies of microfluidic-based LNP production methods to obtain LNPs for applications as carriers in DDSs. The organic solvent injection method is the most used method to produce LNPs in the size range from 20 to 100 nm [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] . The organic solvent injection method has several advantages for LNP production, including its simple procedures, capability to provide on-demand and tailored syntheses, requirement of small sample volumes (lipids and RNAs), excellent LNP size controllability, and high encapsulation efficiency. Fig. 4 shows the schematic illustration of LNP production by the organic solvent injection method in several types of microfluidic devices. The solvent type is selected depending on the substrate of the device. When polymer microfluidic devices made from polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), polystyrene (PS), and cyclic olefin polymer (COP) are used for LNP production, ethanol, isopropyl alcohol (IPA), or tert-butyl alcohol is selected as the organic solvent. However, microfluidic devices with a glass or silicon substrate can use chloroform or tetrahydrofuran (THF) as the lipid solvent.
As shown in Fig. 4 (a, c), two types of devices have been employed for LNP production, a chip-based device and a capillary-based device. A lipid solution dissolved in organic solvent and a buffer solution are introduced into the microfluidic device. Flow rate, flow rate ratio (FRR: the flow rate of the aqueous solution to the flow rate of the lipid solution), mixing rate, and lipid concentration are the important parameters to control the LNP size. In the microchannel designs of the chip-type device (Fig. 4(a, b) ), the lipid stream is pinched by the aqueous solution stream; then, LNPs are produced at the liquid-liquid interface because of the organic solvent dilution. When the organic solvent is diluted by molecular diffusion, the polarity of the solution will increase at the liquid-liquid interface. Then, the lipid molecules dissolved in the organic solution start to form LNPs. The shorter diffusion length of microfluidic devices allows a more rapid and more homogenous dilution of solvent than conventional batchwise-scale reactors (beakers or flasks). To enhance the dilution rate of organic solvents, a microchannel equipped with micromixer structures that provides a significant potential for controlling the LNP size is used. Table 1 summarizes the characteristics of 3 types of microfluidic devices for LNP production. The flat microchannel is the first reported device for LNP production using hydrodynamic flow focusing [95] . The flat microchannel is fabricated by chemical etching or standard photolithographic technique. The size of LNPs obtained by the flat microchannel ranged from 30 to 250 nm; however, the LNP size controllability is not enough to produce the desired sized LNPs with narrow particle size distribution. To improve the LNP size controllability, a capillary array device and a chaotic mixer device were used in LNP preparation. These devices can produce small-sized LNPs with a narrow particle size distribution, although the capillary array device requires a large volume of aqueous solution. Recently, the chaotic mixer device is the most widely used device for the preparation of LNPs. The chaotic mixer structures enable the rapid dilution of ethanol and showed the best LNP size controllability among the three devices (discussed in more detail below).
LNP production by hydrodynamic flow focusing
Jahn et al. [95] were the first to demonstrate the flow synthesis of LNPs in a microfluidic device by hydrodynamic flow focusing. They used a cross-type glass and silicone microchannel (width, 200 μm; depth, 40 μm) fabricated by chemical etching. A mixture of 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC), cholesterol, and 1 wt% of 1,1′-dioctadecyl-3,3,3′,3′ tetramethilindodicarbocyanine perchlorate (DiIC18) was prepared in IPA (2-propanol) to obtain a lipid solution of 10 mM concentration. The lipid solution and PBS were introduced into the microfluidic device. The flow velocity of lipid solution was fixed to 2.4 mm/s, while the flow velocity of PBS introduction was changed from 2.4 to 59.8 mm/s. The LNP size was controlled over the range of 100 to 300 nm by the flow velocity and FRR.
Jahn et al. [96] also reported the effect of fluid dynamics on the LNP size using the flow focusing microfluidic device. They fabricated two types of microfluidic devices with different channel dimensions. The wider microfluidic device had a 65-μm width and 120-μm height, and the narrower microfluidic device had a 10-μm width and 36-μm height. A mixture of DMPC, cholesterol, and dihexadecyl phosphate (DCP) was used for the lipid solution, and it was adjusted to a total lipid concentration of 5 mM. The FRR was changed from 6 to 48. LNPs had a mean size of 30-70 and 25-75 nm for the 65-and 10-μm-wide microfluidic devices, respectively. The high FRR could produce small-sized LNPs with a narrow particle size distribution. In addition, Jahn et al. [96] carried out computational fluid dynamics (CFD) analyses to understand the relationship between the fluid dynamics and LNP size using the software COMSOL Multiphysics 3.4. Fig. 5 shows the results of four CFD analyses performed at the same flow velocity (0.25 m/s). The width of the IPA stream (the central stream) decreased with the increase in FRR, regardless of the channel geometries. These results indicate that a higher FRR leads to the formation of a narrower concentration gradient of IPA than a lower FRR. In other words, the rapid dilution of alcohol played an important role in the production of small-sized LNPs with a narrow particle size distribution.
The typical chip-type device can generate a 2D hydrodynamic flow focusing stream. This limits the control of the particle size distribution of the LNPs. DeVoe's group reported a glass multicapillary array device to generate a 3D hydrodynamic flow focusing stream (Fig. 6) [104] . Their microfluidic device consisted of seven small capillaries in one large capillary. The lipid solution and aqueous solution were injected into the microfluidic device at the inner and outer capillaries, respectively. A mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)]-2000 (DSPE-PEG 2000) was used for the lipid solution, and the total lipid concentration was adjusted to 10 mM. PBS solution at pH 7.4 was used as the aqueous solution. The flow rate of the aqueous solution was set to 5 mL/min. LNP size distributions were evaluated using a multicapillary device and a typical 2D microfluidic hydrodynamic flow focusing device. The average LNP size obtained using the multicapillary device and the typical 2D microfluidic hydrodynamic focusing was 53 nm (PDI = 0.044) and 51 nm (PDI = 0.083), respectively. DeVoe's group studied the effect of the inner capillary diameter and FRR on the LNP size. The smaller capillary could produce small-sized LNPs because of the generation of a thinner lipid stream line in the microfluidic device. FRRs of 5000:1, 1000:1, and 500:1 produced LNPs of size 53 (PDI = 0.007), 56 (PDI = 0.005), and 66 nm (PDI = 0.047), respectively. Although the LNP size was varied only by about 10 nm, the PDIs were Chaotic mixer (Fig. 4(a) right) PDMS-glass/photolithography 20-250 nm
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Stacking of LNPs in the grooved structures [97, 101, 107] a The LNP size is changed by the flow conditions, concentration of lipids, kinds of lipid and solvents, and additives. Reprinted from [96] with the permission of the American Chemical Society.
decreased ten-fold at the high FRR condition. These results suggest that the narrow concentration gradient contributed to the production of small-sized LNPs with a narrow particle size distribution. DeVoe's group also described a vertical flow focusing technique for LNP production [105] . Unlike the low aspect ratio microfluidic device, the high aspect ratio vertical flow device could prepare LNPs for high throughput and large-scale production. However, the size of the LNPs formed by the method was limited, ranging from 80 to 200 nm. We conjectured that this limitation might be resolved by changing the device dimensions and other parameters, although a trade-off would exist in the production amount.
Micromixer-based LNP production
Generally, the Reynolds (Re) number in microchannels is smaller than 1, and this means that the concentration of organic solvent is dominated by molecular diffusion. To enhance the mixing efficiency, microfluidic devices equipped with micromixer structures, which are the gold standards in the field of microfluidics, have been used [115] [116] [117] [118] . A staggered herringbone micromixer (chaotic micromixer) is the most widely used type of micromixer structure for the production of LNPs. This structure generates chaotic advection in the microchannels, and the fluids or molecules are rapidly mixed by the chaotic advection even if the Re number is smaller than 1 [117] . The dimensions of the micromixer structures, such as width, depth, and height, are essential parameters of the mixing efficiency.
Zhigaltsev et al. [101] reported LNP production using the chaotic micromixer device. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), cholesterol, and triolein were dissolved in ethanol and used as a lipid solution. The concentration of lipid solution was adjusted to 10 mg/mL, and saline was used for the aqueous stream. Fig. 7 shows a schematic illustration of the LNP production process. The microfluidic device could produce the POPC nanoparticles in the size range from 20 to 140 nm by changing the flow rate and FRR. The additives (cholesterol or triolein) affected the LNP size, and 40-to 120-nm-sized LNPs for POPC/cholesterol and 20-to 65-nm-sized LNPs for POPC/triolein formed in the chaotic micromixer device. For this lipid composition, the 20-nmsized LNP is considered as the theoretical minimum size limit according to molecular dynamics simulation results. This suggests that the rapid mixing promoted by chaotic micromixer structures provides better Reprinted from [104] with the permission of the Royal Society of Chemistry. Fig. 7 . Schematic illustration of LNP production process using a microfluidic device with chaotic micromixer structures.
Reprinted from [101] with the permission of the American Chemical Society.
LNP size controllability for DDS applications than the microfluidic device without mixer structures does.
We focused on the analysis of fluid dynamics in microfluidic devices with the aim of understanding the LNP formation behavior [106] . We fabricated microfluidic devices equipped with 0 (without mixer structures), 2, 6, 10, 20, and 69 cycles of chaotic mixer structures to evaluate the effect of mixing efficiency on the LNP size. Fig. 8 shows the dependence of LNP size on the FRR and cycles of chaotic micromixer structures. The microfluidic devices without and with 2 cycles of the structures produced LNPs in the size range of 40 to 150 nm with a wide particle size distribution. However, the microfluidic devices equipped with 10, 29, and 69 cycles produced 30-to 50-nm-sized LNPs with a narrow size distribution. The average LNP size produced by the microfluidic device with 6 cycles of the chaotic micromixer structures was almost the same as that of the LNPs produced by devices equipped with 10 or more structures. However, the LNP size distribution at an FRR of 3 was slightly shifted to a larger size distribution, although no LNP size difference was observed at FRR of 9. These results suggest that the ethanol concentration was not sufficiently low enough to form small-sized LNPs for the device with 6 cycles of chaotic micromixer structures.
To understand the LNP formation process in a microchannel, we investigated the relationship between the LNP size and the mixing performance of microfluidic devices by varying the chaotic micromixer depth [107] . We compared two types of microfluidic devices: the microfluidic device with different depths of their chaotic micromixer structures, 11 μm (the CM_11 device) or 31 μm (the CM_31 device). We expected that the deeper chaotic micromixer structures would show a higher mixing performance than the shallower micromixer would. Fig. 9  (a) represents the mixing performance of the microfluidic devices for a 500-ms time course and the average LNP size formed at an FRR of 3 under different flow rate conditions. The CM_31 device produced 52-nm-sized LNPs at the flow rate of 500 μL/min, and the mixing rate increased rapidly, becoming higher than 80% within 40 ms. The 60-nmsized LNPs were produced at the flow rates of 50 and 100 μL/min. The slopes of the curves showing mixing rates versus residence time were smaller for the 50-and 100-μL/min conditions than that for the 500-μL/min condition. Despite obtaining the same LNP size for the 50-and 100-μL/min conditions, the time necessary to reach the mixing rate of 80% was significantly different. The CM_11 device produced 62-nm LNPs at a flow rate of 500 μL/min; however, 98-and 118-nm LNPs formed at the 100-and 50-μL/min conditions. The slopes of the curves showing mixing rate versus residence time for the formation of 60-nm-sized LNPs were similar and did not depend on the device structures and flow rates. We also studied the relationship between the LNP size and the mixing rate at an FRR of 9 and assumed that rapid mixing from 20% to 40% was the critical factor for controlling the size and producing small-sized LNPs. The mixing rate of 20% and 40% corresponded to the appearance of ethanol concentrations of 80% and 60%. Fig. 9(b) and (c) show the LNP formation process in the microchannel at slower and faster mixing conditions, respectively. We concluded that the residence time at the critical concentration played an important role in the LNP formation process. The small-sized LNPs were formed only under the rapid mixing or diluted condition. The range of critical mixing rate and time-scale for passing through the critical concentration would likely vary depending on the mixing mechanism such as molecular diffusion, chaotic advection, and dean vortex turbulent mixing. However, these findings have led us to establish a design principle for microfluidic devices to control the LNP size more accurately. Chen et al. [97] synthesized LNPs encapsulating siRNA and providing high-throughput screening of lipid-like materials (lipidoids) for siRNA delivery using a microfluidic device with chaotic micromixer structures.
The LNPs were a mixture of cationic lipid, cholesterol, distearoyl phosphatidylcholine (DSPC), and polyethylene glycol modified lipid ((R)-3-[(ω-methoxy-PEG2000-carbamoyl)]-1,2-di-O-tetradecyl-sn-glyceride, referred to as mPEG2000-DMG). Fig. 10(a) summarizes the formation scheme of the siRNA-LNPs. First, Chen et al. confirmed the LNP formation behavior by changing the flow rate. The siRNA-LNPs were prepared by the injection of siRNA solution, lipid mixture, and PBS buffer into the microfluidic device ( Fig. 10(b) to (d) ) at an FRR of siRNA:lipid:buffer = 1:1:2. The LNP size decreased with the increase in flow rate, and it was possible to control the size with good reproducibility using the chaotic micromixer structures. The size of the siRNALNPs ranged from 70 to 100 nm at flow rates of 200 to 40 μL/min. The formation behavior of siRNA-LNPs was similar to that of the neutral phospholipid-based LNPs. In contrast, a microfluidic device without the chaotic micromixer and using the conventional pipetting LNP formation method could not produce siRNA-LNPs smaller than 100 nm. Moreover, Chen et al. synthesized siRNA-LNPs using 70 lipidoids for siRNA delivery and evaluated the gene expression efficiency for both in vitro and in vivo experiments. The siRNA delivery potencies of LNPs and lipoplex showed different dependences on the molecular structure of the cationic lipid.
Cullis's group demonstrated the microfluidic synthesis of siRNAencapsulated LNPs for in vivo delivery, as shown in Fig. 11(a) [119] . They set the base LNP formulation of DLinKC2-DMA, cationic lipid/ DSPC/cholesterol/PEG-c-DMA (N-[(methoxy poly(ethylene glycol) 2000)carbamyl]-1,2-dimyristyloxlpropyl-3-amine), at 40:11.5:47.5:1 mol ratios and an siRNA/lipid ratio of 0.06 (wt/wt). The microfluidic device with the chaotic mixer structures enabled the production of siRNA-LNPs of size in the range 20-100 nm and achieved an siRNA encapsulation efficiency of~100%. The LNP size was controlled by the PEG-lipid composition from 1% to 5%, and the higher PEG-lipid composition yielded smaller-sized LNPs than the lower PEG-lipid composition. Cullis's group evaluated the gene silencing effect of the LNPs by administering them to mice. The composition of lipids and siRNA was optimized to improve the effective dose 50, ED 50 . Optimized siRNA-LNP formulation achieved 50% target gene silencing in hepatocytes at a dose level of 10 μg/kg siRNA in mice. In addition, Cullis's group developed a scaled-up system for the mass production of LNPs by parallelization with 6 microfluidic devices (Fig. 11(b) ). The scaled-up system could produce POPC/cholesterol nanoparticles at a flow rate of 72 mL/min or 580 mg LNP/min. Reprinted from [97] with the permission of the American Chemical Society.
Production of functional LNPs and their applications for DDS carriers
A variety of functionalized LNPs and preparation methods or systems were reported for the application of LNP-based DDS nanocarriers [120] [121] [122] [123] [124] [125] [126] [127] [128] . Table 2 shows a summary of the LNPs prepared by microfluidic devices. For example, an encapsulation of doxorubicin hydrochloride (DOX) is a typical application using microfluidic devices for the production of anticancer nanomedicine. DeVoe's group developed an integrated LNP production system including LNP formation, LNP stabilization, buffer exchange (membrane dialysis), drug loading, and drug mixing regions, as shown in Fig. 12 [120] . Their microfluidic device was composed of three layers: a microchannel for buffer flow (bottom layer), porous cellulose dialysis membrane (middle layer), and microchannel for LNP synthesis, buffer exchange, and drug loading (top layer). The in-line system yielded 225.5 nm ± 44.8 nm LNPs, 190.9 nm ± 43.0 nm DOX-loaded LNPs, and 191.5 nm ± 33.4 nm acridine orange hydrochloride (AO)-loaded LNPs. The Reprinted from [119] with the permission of Elsevier. encapsulation efficiency was 72% and 70% for DOX and AO, respectively. Although the encapsulation efficiency was lower than that of bulk-scale loading due to the shorter incubation time, the in-line system provided a rapid LNP-based drug production in a total time of 3 min. We used a microfluidic device with chaotic mixer structures to fabricate double-lamellar multifunctional envelope-type nanodevices (DMENDs), which consisted of a DNA-polycation condensate core and a lipid bilayer membrane envelope surrounding the core [121] . Positively charged, functional nucleic acid (f-NA; consisting of a mixture of a plasmid DNA and protamine sulfate) cores and small unilamellar vesicles composed of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cardiolipin were separately introduced into the microfluidic device at flow rates of 3-10 μL/min. The average size of the particles ranged from 117.3 to 123.2 nm for the studied flow rate range. We also used the microfluidic device with the chaotic mixer structures to fabricate R8-MENDs from the D-MENDs and stearylated octaarginine (STR-R8, a trans-membrane peptide). The average size of the particles ranged from 136.1 to 224.2 nm and showed a dependency on the flow rate.
Recently, a microfluidic instrument for LNP production called Nanoassemblr™ has become commercially available. The microfluidic device equipped with the chaotic micromixer structures is incorporated into Nanoassemblr. Ramishetti et al. [122] fabricated functional LNPs, which specifically delivered siRNAs to murine CD4 + T cells using Nanoassemblr. LNPs were prepared by mixing the lipid/ethanol solution containing MC3, DSPC, cholesterol, DMG-PEG, and DSPE-PEG Mal at 50:10:38:1.5:0.5 mol ratio. Anti-CD4 monoclonal antibody was reduced by 1-mM DTT to react with the maleimide-functionalized LNPs (CD4-tLNPs). The sizes of the plane LNPs and CD4-tLNPs were 58 ± 6 and 129 ± 5 nm, respectively. The siRNA encapsulation efficiency was 95% regardless of the LNPs fabricated. The CD4-tLNPs showed effective silencing of CD45 in CD4 + T cells at 1 mg/kg body doses. Viricel et al.
[123] used Nanoassemblr to synthesize a cationic switchable lipid and produced its LNPs including siRNA to promote the endosomal escape process. Fig. 13 shows the synthesized lipids and a hypothetical schematic representation of siRNA-LNPs. The diameters of siRNA-LNPs prepared by manual extrusion and microfluidic mixing were~150 and 70-90 nm, respectively. The siRNA transfection efficiency was evaluated in vitro in a HeLa/GFP model. Regardless of the preparation methods, CLS3-based LNPs showed the best GFP knockdown efficiency. Furthermore,~50% factor VII silencing efficiency was observed for CLS3-based LNPs prepared by microfluidic mixing in an in vivo experiment. Nanoassemblr was also used for the formation of dendrimer-RNA nanoparticles [124] . The size of the nanocarriers plays a crucial role in the accumulation of nanomedicines in the target tissues [47] [48] [49] [50] . Cullis's group studied the effects of LNP size, the difference of residence time, and the influence of hepatocyte-specific targeting ligands [125] . The siRNA-LNPs were produced by mixing the lipid/ethanol solution including DMAP-BLP (3-(dimethylamino)propyl(12Z,15Z)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yl]henicosa-12,15-dienoate), DSPC, cholesterol, and PEG-DMG at the mole ratio of 50:10:(39.75 − x):(0.25 + x) and the siRNA/25-mM acetate buffer solutions at pH 4.0 in the microfluidic device. The quantities of cholesterol and PEG-DMG were altered accordingly to ± x. The sizes of LNPs varied from 30 to 115 nm depending on the PEG-DMG concentration. The 30-nm and 80-nm-sized LNPs formed at 5 mol% and 0.5 mol% PEG-DMG, respectively. The different sizes of LNPs were evaluated for hepatocyte gene silencing upon subcutaneous administration (Fig. 14) . LNPs of sizes from 95 to 110 nm exhibited low gene silencing activity, even though PEG-DSG ((R)-2,3-bis(stearyloxy) propyl-1-(methoxy poly (ethylene glycol) 2000 carbamate) LNPs could reduce the FVII level to 60% at 5 mg/kg dose. Despite their accumulation performance in the liver, the smallest-sized LNPs (30 nm) did not show high gene silencing performance, regardless of the PEG lipids. The medium-sized LNPs (~45 nm) showed the best gene silencing, and the FVII levels were reduced by 60% and 80% at 1 mg/kg dose and 90% and 95% at 5 mg/kg dose for PEG-DMG LNPs and PEG-DSG LNPs, respectively. In addition, 45-nm-sized PEG-DSG LNPs resulted in 50% FVII protein reduction for at least 7 days by a single injection of 1 mg/kg, while PEG-DMG LNPs gave the reduction for 4 days. However, 35-nm-sized PEG-DSG LNPs with 0.5 mol% of GalNAc-PEG (Nacetylgalactosamine cluster-conjugated PEG-DS) improved the gene silencing activity and showed 90% FVII knockdown for at least 7 days. These results suggest that the suitably functionalized small-sized LNPs could effectively accumulate in target tissues while retaining a high gene knockdown activity.
We investigated the physicochemical properties of siRNA-loaded LNPs with different diameters (32 to 67 nm) for siRNA delivery [48] . The LNPs were composed of a pH-sensitive cationic lipid named YSK05, cholesterol, and 1, 2-dimirystoyl-sn-glycero, methoxyethyleneglycol 2000 ether (PEG-DMG) at a molar ratio of 70/30/1-3 or 50/50/1-3. Fig. 15(a) represents the schematic illustration of the preparation process of the LNPs. For YSK05-based LNPs, their diameter varied in the size range from 37.3 to 67.1 nm, depending on the amount of PEG-DMG, for the 1% PEG-LNPs and 3% PEG-LNPs (Fig. 15(b) ). However, the encapsulation efficiency of siRNA was nearly 100%, and no dependency on the amount of PEG-DMG was observed. In the YSK05-based LNP formation, the amount of cholesterol was important for controlling the physical stability and minimizing the leakage of siRNA in the circulated blood. The LNP sizes containing 50% cholesterol were 47.0 and 31.3 nm for 1% PEG-LNPs and 3% PEG-LNPs, respectively. The cholesterol-rich 3%PEG-LNPs had better siRNA delivery efficiency than 1% PEG-LNPs, although it had a lower gene silencing activity due to the absorption of a large amount of serum proteins. We considered that the problems could be resolved by optimizing the PEG structure or the use of environment-responsive technologies for the production of highly functional LNP-based nanomedicine.
Anderson's group reported a combination of LNP-mediated delivery of Cas9 mRNA with adeno-associated viruses encoding a sgRNA (singleguide RNA) and a repair template to promote a disease gene [98] . The functionalized LNPs were synthesized with C-12-200, cholesterol, C14PEG2000, DOPE, and arachidonic acid at a weight ratio of 50:20:10:10:10. Cas9 mRNA had a lipid:mRNA weight ratio of 20:1. The compounds were rapidly mixed in a microfluidic device and formed Reprinted from [123] with the permission of the American Chemical Society.
120-nm-sized LNPs. The LNPs exhibited N6% corrected hepatocytes, and homology-directed repair was confirmed. In another study, Anderson's group demonstrated the synthesis of 1400 degradable lipidoids in an attempt to understand the effect of molecular structures on the siRNA delivery efficiency [126] . The sizes of LNPs were changed from 60 to 120 nm, depending on the lipidoids. The LNPs were evaluated by in vitro screening, in vivo gene silencing and biodistribution in mice, and a safety assessment. Fig. 16 shows the relationship between the functional properties of lipidoids and in vivo FVII activity. The LNPs composed of O 13 tail, three or more alkyl-amine groups, and a tertiary-amine group showed excellent FVII silencing.
In this section, we described how microfluidic devices have provided researchers with promising approaches for applications of sizecontrolled and functionalized LNPs in DDSs. Future investigations will need to target understanding the effects of physical properties of LNPs, including their size, structure, and composition, on in vivo kinetics, delivery efficiency, and in vivo activity.
Separation of EVs using microfluidic devices
The separation of EVs using microfluidic devices is a fundamental technique for diagnostics and medical applications. Mainly, EVs are separated by the differences in particle size, mass, electric charge, and ligands at the surface; this is the same as that in conventional methods. Microfluidic devices can better promote the separation efficiency and performance than conventional methods by using their unique characteristics in combination with the use of an external force such as hydrodynamic force, electric field, or acoustic field. In this section, we review separation techniques of exosomes using micro-nanofluidic devices [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] .
Chen et al. [131] reported a microfluidic device that separates exosomes based on the immunoaffinity method. The microchannel surface was first modified by 3-meraptopropyl trimethoxysilane and then crosslinked with NeutrAvidin, followed by immobilization using biotinylated anti-CD63, control IgG, or anti-CD4 solution. The separation performance was observed by SEM image analysis, fluorescence image Reprinted from [125] with the permission of Elsevier. Reprinted from [126] with the permission of Nature Publishing Group. analysis, RT-PCR, and nested PCR analyses. The average amount of RNA extracted by the microfluidic device was 30.88 ng/400 μL from the serum of a patient with glioblastoma multiforme, whereas the amount was 2 to 4 ng/400 μL from a normal control. Kanwar et al. [132] developed ExoChip (Fig. 17) for the on-chip separation and measurement of exosomes ( Fig. 17(a) ). The strategy they employed in ExoChip is represented in Fig. 17(b) and (c). There are three steps for exosome characterization: (1) capturing exosomes in a serum sample, (2) labeling exosomes using fluorescence dye (DiO), and (3) measuring the fluorescence intensity using a plate reader. ExoChip could distinguish the difference in exosome levels and the protein (CD63 and Rab5) expression levels among the serum samples of controls, healthy individuals, and patients with pancreatic cancer. Fang et al. [133] fabricated a microfluidic platform to apply immunomagnetic particles (magnetic nanoparticles with CD63 antibody, designated Mag-CD63) for exosome quantification. Akagi et al. [134] reported microchip-based immunoelectrophoresis to determine the surface marker of EVs. EVs collected from the culture supernatant of MDA-MB-231 human breast cancer cells and the blood of mice implanted with MDA-MB-231 cells were analyzed by immunoelectrophoresis. Peaks of the complex of antibodies-EVs were observed near 0 mV, which was slightly positive compared with normal IgG, regardless of the samples.
Wunsch et al. [135] demonstrated the separation of nanoparticles of size 20-110 nm by using a deterministic lateral displacement (DLD) pillar array and applied the device for exosome separation. The principle of DLD was first reported by Huang et al. [142] in 2004. Particles flowing into the microfluidic device were deterministically separated based on the particle size and the gap of nanopillar array in the microfluidic device. To separate nanoparticles and exosomes, Eunsch et al. minimized a DLD device using nanofabrication techniques. Fig. 18(a) and (b) show the separation of nanometer-sized (50 and 100 nm) polystyrene beads and exosomes. For bead separation, the particles were gradually separated on passing thorough the nanopillar array section with 235-nm gaps, and they were completely separated on reaching the outlet. For exosome separation, exosomes of 100 nm or smaller could be recovered from human-urine-derived sample using the nano-DLD device.
In addition to the above techniques and devices, a centrifugal microfluidic system called Exodisc, pinched flow systems, a viscoelasticbased microfluidic system for size-dependent separation, and a surface acoustic wave separation system were developed to separate exosomes from biofluids [136] . These microfluidic devices and techniques will expand the use of EVs, including exosomes, for applications as DDS nanocarriers.
Conclusion
In this review, we summarized microfluidic devices and techniques for size-controlled LNP production and separation of EVs for DDS applications. The principles of LNP formation and EV separation are basically the same as those of conventional methods. However, the special characteristics of microfluidic devices make it possible to produce precise sizecontrolled LNPs and separate EVs from real samples effectively. Further investigations are required to understand the effects of LNP size on the Fig. 18 . Separation of 50-and 100-nm-sized particles using the nano DLD device: (a) polystyrene beads and (b) exosomes. The nanoparticles are introduced into the DLD device from the center stream of the flow focusing junction. Reprinted from [135] with the permission of Nature Publishing Group. stability, in vivo kinetics, and performance of nano-DDSs. However, understanding the size effect of DDS nanocarriers will provide researchers with indispensable information for developing next-generation nanomedicines and elucidating the relationship between EVs and diseases. Improving LNP size controllability using the microfluidic device remains a major challenge for understanding the effects of LNP size on the in vivo potency of LNPs. Although the chaotic mixer device is the most widely used for LNP production, the chaotic mixer device requires a high flow rate of aqueous solution containing drugs to produce smallsized LNPs. Therefore, the development of novel microfluidic device that can produce small-sized LNPs at low flow rate is desired for reducing the use of expensive materials. In addition, clogging of LNPs in the grooves of the chaotic mixer should be resolved for continuous LNP production. We presume that the chaotic mixer structure is not necessarily required for producing small-sized LNPs and controlling LNP size precisely from the view point of LNP formation process. Thus, the novel microfluidic platforms consisting of a more simple structure will be developed to expand the utility of microfluidic-based LNP production.
Unlike the conventional LNP production methods, the microfluidicbased methods can produce LNPs of lowest size on demand. The ondemand LNP production promises new applications of microfluidic devices for the high throughput and loss-less screening of LNP-based pharmaceutical candidate compounds and tailor-made medications. In addition, microfluidic devices can integrate the functions of pre-and posttreatment into the LNP production and increase the production amount by numbering up or parallelization of the devices. Microfluidic platforms have suitable characteristics for practical applications to the production of next-generation LNP-based nanomedicines. We expect that the microfluidic platforms will become a new gold standard for LNP production and separation of EVs.
